Citation Information :
Sarin BC, Grover S, Singh P. To Study the Association of Serum Uric Acid Levels with Severity of Chronic Obstructive Pulmonary Disease. Indian J Chest Dis Allied Sci 2024; 66 (4):113-117.
Background: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes airflow obstruction which leads to hypoxia. Serum uric acid is increased in hypoxic states as well as in systemic inflammatory conditions. The purpose of the present study was to assess whether the higher value of serum uric acid corresponds with the severity of COPD as per spirometric classification of COPD.
Material and methods: This cross-sectional study included 294 spirometry-diagnosed patients of COPD as per Global Initiative for Chronic Obstructive Lung Disease criteria. Serum uric acid levels were tested on all the patients. The patients with raised serum uric acid levels were further categorized according to severity COPD grade. Reference of normal serum uric acid levels among males was taken as 3.5−8.5 mg/dL and among females as 2.5−6.2 mg/dL.
Results: In the present study of 294 patients, maximum patients, i.e., 59.5%, were in moderate COPD grade. The mean serum uric acid value in male subjects was 5.9 ± 2.066 mg/dL, while in female subjects the mean serum uric acid value was 6.31 ± 1.93 mg/dL. About 85 (22 males and 63 females) had serum uric acid values out of the normal range. In males, maximum (41.6%) were in severe COPD grade, whereas in females maximum (80.8%) were in moderate COPD grade. Severe COPD grade showed statistically significant (p = 0.037) association with raised serum uric acid levels in both male and female subjects.
Conclusion: The study concludes that mean uric acid levels progressively increased as the COPD grade increased from I to IV. Since serum uric acid levels were raised in COPD patients mainly in the severe COPD grade, it serves as a useful parameter for assessing disease severity and hypoxemia in known COPD patients.
Celli B, Fabbri L, Criner G, et al. Definition and nomenclature of chronic obstructive pulmonary disease: Time for its revision. Am J Respir Crit Care Med 2022;206(11):1317−1325. DOI: 10.1164/rccm.202204- 0671PP.
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3(11):442−445. DOI: 10.1371/journal.pmed.0030442.
Yin P, Jiang CQ, Cheng KK, et al. Passive smoking exposure and risk of COPD among adults in China: The Guangzhou Biobank Cohort Study. Lancet 2007;370(9589):751−757. DOI: 10.1016/S0140-6736(07) 61378-6.
GBD compare—Viz hub [Internet]. Institute for Health Metrics and Evaluation [Accessed Oct 2023]. Available from: https://vizhub.healthdata.org/gbd-compare/.
Guo C, Zhang Z, Lau AK, et al. Effect of long-term exposure to fine particulate matter on lung function decline and risk of chronic obstructive pulmonary disease in Taiwan: A longitudinal, cohort study. Lancet Planet Health 2018;2(3):e114−e125. DOI: 10.1016/S2542-5196(18)30028-7.
Nicks ME, O'Brien MM, Bowler RP. Plasma antioxidants are associated with impaired lung function and COPD exacerbations in smokers. COPD 2011;8(4):264−269. DOI: 10.3109/15412555.2011.579202.
Woolliscroft JO, Colfer H, Fox IH. Hyperuricemia in acute illness: A poor prognostic sign. Am J Med 1982;72:58−62. DOI: 10.1016/0002-9343(82)90578-2.
Voelkel MA, Wynne KM, Badesch DB, et al. Hyperuricemia in severe pulmonary hypertension. Chest 2000;117(1):19−24. DOI: 10.1378/chest.117.1.19.
Pascual-Figal DA, Hurtado-Martinez JA, Redondo B, et al. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail 2007;9(5):518−524. DOI: 10.1016/j.ejheart.2006.09.001.
Holme I, Aastveit AH, Hammar N. Uric acid and risk of myocardial infarction, smoke and congestive heart failure in 417,734 men and women in the apolipoprotein mortality risk study (AMORIS). J Intern Med 2009;266(6):558−570. DOI: 10.1111/j.1365-2796.2009.02133.x.
Vestbo J, Hurd SS, Augusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347−365. DOI: 10.1164/rccm.201204-0596PP.
Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: The global lung function 2012 equations. Eur Respir J 2012;40(6):1324−1343. DOI: 10.1183/09031936.00080312.
Buhr RG, Barjaktarevic IZ, Quibrera PM, et al. Reversible airflow obstruction predicts future chronic obstructive pulmonary disease development in the SPIROMICS cohort: An observational cohort study. Am J Respir Crit Care Med 2022;206(5):554−562. DOI: 10.1164/rccm.202201-0094OC.
Tietz N. Fundamentals of clinical chemistry. Philadelphia, PA: WB Saunders; 1976.
Huijsmans RJ, de Haan A, ten Hacken NN, et al. The clinical utility of the GOLD classification of COPD disease severity in pulmonary rehabilitation. Respir Med 2008;102(1):162−171 DOI: 10.1016/j.rmed.2007.07.008.
Bartziokas K, Papaioannou AI, Loukides S, et al. Serum uric acid as a predictor of mortality and future exacerbations of COPD. Eur Respir J 2014;43(1):43−53. DOI: 10.1183/09031936.00209212.
Galamay JR. Association of serum uric acid levels and outcomes of patients with COPD: A prospective cohort study. Chest 2017;152(4):A789. DOI:10.1183/13993003.congress-2018.pa4076.
Embarak S, Sileem AE, Abdrabboh M, et al. Serum uric acid as a biomarker for prediction of outcomes of patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. Egypt J Bronchol 2014;8:115−120. DOI: 10.4103/1687-8426.145703.
Sarangi R, Varadhan N, Bahinipati J, et al. Serum uric acid in chronic obstructive pulmonary disease: A hospital based case control study. J Clin Diagn Res 2017;11(9):BC09−BC13. DOI: 10.7860/JCDR/2017/29300.10605.
Li H, Chen Y. Serum uric acid level as a biomarker for chronic obstructive pulmonary disease: A meta-analysis. J Int Med Res 2021;49(1):300060520983705. DOI: 10.1177/0300060520983705.
Tanwar Y, Singh C, Chakrabarty S. Comparison of serum uric acid levels in patients with stable chronic obstructive pulmonary disease and patients with acute exacerbation. J Assoc Physicians India 2022;70(4):11−12. PMID: 35443457.